Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nano HoldingsTSE:4571 39 Debt-to-Equity is 0.45 as of Mar. 2026, which is 55% above its 10-year median of 0.29. GuruFocus rates TSE:4571 with a GF Score™ of 39/100 and a GF Value™ of 円186.31 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Biotechnology companies, Nano Holdings ranks worse than 67.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nano Holdings's Debt-to-Equity or its related term are showing as below:
TSE:4571'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.29 Max: 0.53
Current: 0.36
During the past 13 years, the highest Debt-to-Equity Ratio of Nano Holdings was 0.53. The lowest was 0.20. And the median was 0.29.
TSE:4571's Debt-to-Equity is ranked worse than 67.89% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs TSE:4571: 0.36
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nano Holdings Debt-to-Equity Related Terms
Nano Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nano Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4571 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nano Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nano Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nano Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nano Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nano Holdings (TSE:4571) has a Debt-to-Equity of 0.45 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nano Holdings and its competitors. This is 55% above median its historical median of 0.29. Over the past decade, Nano Holdings' Debt-to-Equity has ranged from 0.20 to 0.53. According to the industry distribution chart, Nano Holdings ranks #649 out of 956 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Nano Holdings' Debt-to-Equity too high?
Nano Holdings' current Debt-to-Equity of 0.45 is 55% above median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 0.53. The Biotechnology industry median Debt-to-Equity is 0.16. Nano Holdings' value of 0.45 is 181.3% above this industry median. Based on the distribution chart, Nano Holdings ranks #649 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nano Holdings has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nano Holdings' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nano Holdings ranks #649 out of 956 companies for Debt-to-Equity. This places Nano Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Nano Holdings' value of 0.45 is 181.3% above this benchmark. Historically, Nano Holdings' own Debt-to-Equity has ranged from 0.20 to 0.53 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.16, Nano Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nano Holdings's current Debt-to-Equity of 0.45 is 181.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nano Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nano Holdings's current Debt-to-Equity is 0.45, which is 55% above median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Nano Holdings (TSE:4571) is currently considered Possible Value Trap. The stock's GF Value™ is 円186.31, compared to a current price of 円103.00 — trading 44.7% below its estimated fair value. The current Debt-to-Equity is 0.45, which is 55% above median its 10-year median of 0.29 and 181.3% above the Biotechnology industry median of 0.16. Nano Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nano Holdings (TSE:4571), the current Debt-to-Equity is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nano Holdings (TSE:4571) Overvalued in 2026?
Based on GuruFocus' analysis, Nano Holdings stock appears to be undervalued.
The current stock price of 円103.00 is trading 44.7% below its estimated GF Value™ of 円186.31.
GuruFocus considers Nano Holdings to be Possible Value Trap.
Key valuation signals for TSE:4571:
Debt-to-Equity: 0.45 (55% above median its 10-year median of 0.29)
GF Value™: 円186.31 vs. price of 円103.00 (44.7% below fair value)
Industry Position: 181.3% above the Biotechnology median (#649 of 956)
No single metric tells the full story. See the TSE:4571 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nano Holdings Inc formerly, Nano Mrna Co Ltd is engaged in the research and development of pharmaceuticals using micellar nanoparticle technology. The Group's business is a single segment that involves research and development, manufacturing, and sales of pharmaceuticals and other products, as well as related operations.
39GF Score
Get the complete analysis for TSE:4571
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4571 has been successfully added to your 
